We found for
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
![Risperidone Cover Page](https://www.ohe.org/wp-content/uploads/2019/07/Risperidone-Cover-Page.jpg)
Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
![IBP Cover](https://www.ohe.org/wp-content/uploads/2019/06/IBP-Cover.jpg)
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
![Front Cover (V2)](https://www.ohe.org/wp-content/uploads/2019/07/Front-Cover-V2_0.jpg)
Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
![Issues Surrounding the Estimation of the Opportunity Image](https://www.ohe.org/wp-content/uploads/2018/08/Issues-Surrounding-the-Estimation-of-the-Opportunity-Image_0.jpg)
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
![Medicines Tracker Report Image](https://www.ohe.org/wp-content/uploads/2017/12/Medicines-Tracker-Report-Image_0.jpg)
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
![Access to OMPs](https://www.ohe.org/wp-content/uploads/2017/03/Access-to-OMPs.jpg)
The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
![Value_of_knowing_and_knowing_the_value_Cover copy](https://www.ohe.org/wp-content/uploads/2024/06/Value_of_knowing_and_knowing_the_value_Cover-copy.png)